Antiviral Prophylaxis for Chemotherapy-Induced Reactivation of Chronic Hepatitis B Virus Infection

Clinics in Liver Disease

Volumn 11, Issue 4, 2007, Pages 965-991

  Kohrt, Holbrook E ^a   Ouyang, Daniel L ^b   Keeffe, Emmet B ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ARABINOSIDE; BLEOMYCIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOSINE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EMTRICITABINE; FAMCICLOVIR; FLUDARABINE; FLUOROURACIL; GANCICLOVIR; IDARUBICIN; INTERFERON; LAMIVUDINE; METHOTREXATE; NAVELBINE; NUCLEOSIDE ANALOG; PREDNISOLONE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TENOFOVIR; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VIRUS DNA;

AMINOTRANSFERASE BLOOD LEVEL; BREAST CANCER; CHRONIC HEPATITIS; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; DEMOGRAPHY; DISEASE CARRIER; DISEASE COURSE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DISEASE TRANSMISSION; DIZZINESS; FOLLOW UP; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; LEUKEMIA; LIVER CELL CARCINOMA; LIVER FAILURE; LYMPHOMA; NASOPHARYNX CANCER; NAUSEA; OUTCOME ASSESSMENT; PANCREATITIS; PRACTICE GUIDELINE; PREVALENCE; REVIEW; RISK ASSESSMENT; SURVIVAL RATE; SYMPTOM; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT PLANNING; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS REACTIVATION;

ANTIVIRAL AGENTS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; VIRUS ACTIVATION;

EID: 35548974225     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2007.08.006     Document Type: Review

References (153)

1. Lavanchy D.D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11 2 (2004) 97-107
2. Kane M. Global programme for control of hepatitis B infection. Vaccine 13 Suppl 1 (1995) S47-S49
3. Kane M. Epidemiology of hepatitis B infection in North America. Vaccine 13 Suppl 1 (1995) S16-S17
4. Lee W.M. Hepatitis B virus infection. N Engl J Med 337 24 (1997) 1733-1745
5. Amin J., Law M.G., Bartlett M., et al. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 368 9539 (2006) 938-945
6. Fattovich G., Brollo L., Alberti A., et al. Spontaneous reactivation of hepatitis B virus infection in patients with chronic type B hepatitis. Liver 10 3 (1990) 141-146
7. Tong M.J., Sampliner R.E., Govindarajan S., et al. Spontaneous reactivation of hepatitis B in Chinese patients with HBsAg-positive chronic active hepatitis. Hepatology 7 4 (1987) 713-718
8. Davis G.L., and Hoofnagle J.H. Reactivation of chronic type B hepatitis presenting as acute viral hepatitis. Ann Intern Med 102 6 (1985) 762-765
9. Davis G.L., Hoofnagle J.H., and Waggoner J.G. Spontaneous reactivation of chronic hepatitis B virus infection. Gastroenterology 86 2 (1984) 230-235
10. Hoofnagle J.H., Dusheiko G.M., Schafer D.F., et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 96 4 (1982) 447-449
11. Steinberg J.L., Yeo W., Zhong S., et al. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role. J Med Virol 60 3 (2000) 249-255
12. Yeo W., Chan P.K., Zhong S., et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62 3 (2000) 299-307
13. McMillan J.S., Shaw T., Angus P.W., et al. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology 22 1 (1995) 36-43
14. Markovic S., Drozina G., Vovk M., et al. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy: a prospective study in 305 patients. Hepatogastroenterology 46 29 (1999) 2925-2930
15. Persico M., De Marino F., Russo G.D., et al. Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood 99 2 (2002) 724-725
16. Kumagai K., Takagi T., Nakamura S., et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol 8 Suppl 1 (1997) 107-109
17. Nakamura Y., Motokura T., Fujita A., et al. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies: survey in Japan, 1987-1991. Cancer 78 10 (1996) 2210-2215
18. Liao C.A., Lee C.M., Wu H.C., et al. Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma. Br J Haematol 116 1 (2002) 166-169
19. Liang R., Lau G.K., and Kwong Y.L. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 17 1 (1999) 394-398
20. Lau G.K., Leung Y.H., Fong D.Y., et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 99 7 (2002) 2324-2330
21. Alexopoulos C.G., Vaslamatzis M., and Hatzidimitriou G. Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. Br J Cancer 81 1 (1999) 69-74
22. Idilman R. Lamivudine prophylaxis in HBV carriers with haemato-oncological malignancies who receive chemotherapy. J Antimicrob Chemother 55 6 (2005) 828-831
23. Ustun C., Koc H., Karayalcin S., et al. Hepatitis B virus infection in allogeneic bone marrow transplantation. Bone Marrow Transplant 20 4 (1997) 289-296
24. Chen P.M., Chiou T.J., Fan F.S., et al. Fulminant hepatitis is significantly increased in hepatitis B carriers after allogeneic bone marrow transplantation. Transplantation 67 11 (1999) 1425-1433
25. Silvestri F., Ermacora A., Sperotto A., et al. Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation. Br J Haematol 108 2 (2000) 394-396
26. Rossi G., Pelizzari A., Motta M., et al. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 115 1 (2001) 58-62
27. Leaw S.J., Yen C.J., Huang W.T., et al. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol 83 5 (2004) 270-275
28. Lim L.L., Wai C.T., Lee Y.M., et al. Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. Aliment Pharmacol Ther 16 11 (2002) 1939-1944
29. Lok A.S., Liang R.H., Chiu E.K., et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: report of a prospective study. Gastroenterology 100 1 (1991) 182-188
30. Cheng A.L. Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma. Blood 87 3 (1996) 1202
31. Vento S., Di Perri G., Garofano T., et al. Reactivation of hepatitis B in AIDS. Lancet 2 8654 (1989) 108-109
32. Marcellin P., Giostra E., Martinot-Peignoux M., et al. Redevelopment of hepatitis B surface antigen after renal transplantation. Gastroenterology 100 5 Pt 1 (1991) 1432-1434
33. Carman W.F., Korula J., Wallace L., et al. Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA. Lancet 345 8962 (1995) 1406-1407
34. Kubo S., Nishiguchi S., Hamba H., et al. Reactivation of viral replication after liver resection in patients infected with hepatitis B virus. Ann Surg 233 1 (2001) 139-145
35. Rostoker G., Rosenbaum J., Ben Maadi A., et al. Reactivation of hepatitis B virus by corticosteroids in a case of idiopathic nephrotic syndrome. Nephron 56 2 (1990) 224
36. Lau J.Y., Lai C.L., Lin H.J., et al. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Q J Med 73 270 (1989) 911-917
37. Keeffe E.B., Dieterich D.T., Han S.H., et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2 2 (2004) 87-106
38. Lok A.S., and McMahon B.J. Chronic hepatitis B: update of recommendations. Hepatology 39 3 (2004) 857-861
39. McMahon B.J., Bulkow L., Harpster A., et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 32 4 Pt 1 (2000) 842-846
40. Vento S., di Perri G., Luzzati R., et al. Clinical reactivation of hepatitis B in anti-HBs-positive patients with AIDS. Lancet 1 8633 (1989) 332-333
41. Dai M.S., Wu P.F., Lu J.J., et al. Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus undergoing cytotoxic chemotherapy: a longitudinal study. Support Care Cancer 12 3 (2004) 191-196
42. Dai M.S., Wu P.F., Shyu R.Y., et al. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int 24 6 (2004) 540-546
43. Yeo W., Chan P.K., Hui P., et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 70 4 (2003) 553-561
44. Lau G.K., Liang R., Wu P.C., et al. Use of famciclovir to prevent HBV reactivation in HBsAg-positive recipients after allogeneic bone marrow transplantation. J Hepatol 28 3 (1998) 359-368
45. Rossi G. Prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with hemato-oncological neoplasias treated with chemotherapy. Leuk Lymphoma 44 5 (2003) 759-766
46. Papatheodoridis G.V., Dimou E., and Papadimitropoulos V. Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. Am J Gastroenterol 97 7 (2002) 1618-1628
47. Rizzetto M., Volpes R., and Smedile A. Response of pre-core mutant chronic hepatitis B infection to lamivudine. J Med Virol 61 3 (2000) 398-402
48. Gish R.G., Lau J.Y., Brooks L., et al. Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients. Hepatology 23 1 (1996) 1-7
49. ter Borg F., Smorenburg S., de Man R.A., et al. Recovery from life-threatening, corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy. Dig Dis Sci 43 10 (1998) 2267-2270
50. Lau J.Y., Bird G.L., Gimson A.E., et al. Treatment of HBV reactivation after withdrawal of immunosuppression. Lancet 337 8744 (1991) 802
51. Dienstag J.L., Perrillo R.P., Schiff E.R., et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 333 25 (1995) 1657-1661
52. Dornsife R.E., and Averett D.R. In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in human immunodeficiency virus-positive humans. Antimicrob Agents Chemother 40 2 (1996) 514-519
53. Swartz M.N. Mitochondrial toxicity: new adverse drug effects. N Engl J Med 333 17 (1995) 1146-1148
54. Tanikawa K., Hayashi N., and Ichida F. A placebo-controlled phase III study of lamivudine in Japanese patients with chronic hepatitis B infection. Hepatology 26 (1997) 259A [abstract]
55. ter Borg F., Smorenburg S., and De Man R.A. Successful treatment with lamivudine for fulminant hepatic failure caused by chemotherapy-induced hepatitis B virus reactivation. Gastroenterology 112 (1997) A1399 [abstract]
56. Benhamou Y., Dohin E., Lunel-Fabiani F., et al. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet 345 8946 (1995) 396-397
57. Gutfreund K.S., Williams M., George R., et al. Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance. J Hepatol 33 3 (2000) 469-475
58. Perrillo R.P., Rakela J., and Martin P. Lamivudine for hepatitis B after liver transplantation. Hepatology 24 (1996) 182A [abstract]
59. Clark F.L., Drummond M.W., Chambers S., et al. Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma. Ann Oncol 9 4 (1998) 385-387
60. Picardi M., Selleri C., De Rosa G., et al. Lamivudine treatment for chronic replicative hepatitis B virus infection after allogeneic bone marrow transplantation. Bone Marrow Transplant 21 12 (1998) 1267-1269
61. Yeo W., Steinberg J.L., Tam J.S., et al. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J Med Virol 59 3 (1999) 263-269
62. Lee W.C., Wu M.J., Cheng C.H., et al. Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients. Am J Kidney Dis 38 5 (2001) 1074-1081
63. Cainelli F., Longhi M.S., Concia E., et al. Failure of lamivudine therapy for chemotherapy-induced reactivation of hepatitis B. Am J Gastroenterol 96 5 (2001) 1651-1652
64. Al-Taie O.H., Mork H., Gassel A.M., et al. Prevention of hepatitis B flare-up during chemotherapy using lamivudine: case report and review of the literature. Ann Hematol 78 5 (1999) 247-249
65. Ahmed A., and Keeffe E.B. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection. Am J Gastroenterol 94 1 (1999) 249-251
66. Henkes M., Martin S., Einsele H., et al. Successful antiviral treatment for fulminant reactivated hepatitis B after autologous stem cell transplantation and prophylaxis during subsequent allogeneic stem cell transplantation. Ann Hematol 81 6 (2002) 343-346
67. Murakami R., Amada N., Sato T., et al. Reactivation of hepatitis and lamivudine therapy in 11 HBsAg-positive renal allograft recipients: a single centre experience. Clin Transplant 20 3 (2006) 351-358
68. Shitrit A.B.-G., Kramer M.R., Bakal I., et al. Lamivudine prophylaxis for hepatitis B virus infection after lung transplantation. Ann Thorac Surg 81 5 (2006) 1851-1852
69. Prakoso E., Strasser S.I., Koorey D.J., et al. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors. Clin Transplant 20 3 (2006) 369-373
70. Shibolet O., Ilan Y., Gillis S., et al. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 100 2 (2002) 391-396
71. Lee G.-W., Ryu M.-H., Lee J.-L., et al. The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with non-Hodgkin's lymphoma who receive cytotoxic chemotherapy. J Korean Med Sci 18 6 (2003) 849-854
72. Fischer K.P., Gutfreund K.S., and Tyrrell D.L. Lamivudine resistance in hepatitis B: mechanisms and clinical implications. Drug Resist Updat 4 2 (2001) 118-128
73. Chan H.L., Chui A.K., Lau W.Y., et al. Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophylaxis. Clin Transplant 18 3 (2004) 295-300
74. Bain V.G., Kneteman N.M., Ma M.M., et al. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 62 10 (1996) 1456-1462
75. Chu C.-M., and Liaw Y.-F. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis 26 2 (2006) 142-152
76. Jang J.W., Choi J.Y., Bae S.H., et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 43 2 (2006) 233-240
77. Idilman R., Arat M., Soydan E., et al. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepat 11 2 (2004) 141-147
78. Yeo W., Hui E.P., Chan A.T., et al. Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine. Am J Clin Oncol 28 4 (2005) 379-384
79. Yeo W., Ho W.M., Hui P., et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat 88 3 (2004) 209-215
80. Hui C.K., Cheung W.W., Au W.Y., et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 54 11 (2005) 1597-1603
81. Vassiliadis T., Garipidou V., Tziomalos K., et al. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy: a prospective case series. Am J Hematol 80 3 (2005) 197-203
82. el-Sayed M.H., Shanab G., Karim A.M., et al. Lamivudine facilitates optimal chemotherapy in hepatitis B virus-infected children with hematological malignancies: a preliminary report. Pediatr Hematol Oncol 21 2 (2004) 145-156
83. Lau G.K., Yiu H.H., Fong D.Y., et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 125 6 (2003) 1742-1749
84. Li Y.-H., He Y.-F., Jiang W.-Q., et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 106 6 (2006) 1320-1325
85. Yeo W., Chan P.K., Chan H.L., et al. Hepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis. J Med Virol 65 3 (2001) 473-477
86. Simpson N.D., Simpson P.W., Ahmed A.M., et al. Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with lamivudine. J Clin Gastroenterol 37 1 (2003) 68-71
87. Su W.P., Wen C.C., Hsiung C.A., et al. Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients. World J Gastroenterol 11 34 (2005) 5283-5288
88. Yeo W., Zee B., Zhong S., et al. Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 90 7 (2004) 1306-1311
89. Zekri A.R., Mohamed W.S., Samra M.A., et al. Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation. Transpl Immunol 13 4 (2004) 305-311
90. Zhong S., Yeo W., Schroder C., et al. High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat 11 1 (2004) 55-59
91. Dai M.S., Lu J.J., Chen Y.C., et al. Reactivation of precore mutant hepatitis B virus in chemotherapy-treated patients. Cancer 92 11 (2001) 2927-2932
92. Carman W.F., Fagan E.A., Hadziyannis S., et al. Association of a precore genomic variant of hepatitis B virus with fulminant hepatitis. Hepatology 14 2 (1991) 219-222
93. Levy P., Marcellin P., Martinot-Peignoux M., et al. Clinical course of spontaneous reactivation of hepatitis B virus infection in patients with chronic hepatitis B. Hepatology 12 3 Pt 1 (1990) 570-574
94. Endo T., Sakai T., Fujimoto K., et al. A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 27 4 (2001) 433-436
95. Kawatani T., Suou T., Tajima F., et al. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haematol 67 1 (2001) 45-50
96. Ishiga K., Kawatani T., Suou T., et al. Fulminant hepatitis type B after chemotherapy in a serologically negative hepatitis B virus carrier with acute myelogenous leukemia. Int J Hematol 73 1 (2001) 115-118
97. Law J.K., Ho J.K., Hoskins P.J., et al. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 46 7 (2005) 1085-1089
98. Hui C.-K., Cheung W.W.W., Zhang H.-Y., et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 131 1 (2006) 59-68
99. Yuen M.F., Wong D.K., Sablon E., et al. Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine. Antivir Ther 8 6 (2003) 531-534
100. Yuen M.F., Tanaka Y., and Lai C.L. Hepatitis B genotypes in chronic hepatitis B and lamivudine therapy. Intervirology 46 6 (2003) 373-376
101. Yeo W., Lam K.C., Zee B., et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 15 11 (2004) 1661-1666
102. Nagamatsu H., Kumashiro R., Itano S., et al. Investigation of associating factors in exacerbation of liver damage after chemotherapy in patients with HBV-related HCC. Hepatol Res 26 4 (2003) 293-301
103. Caselitz M., Link H., Hein R., et al. Hepatitis B associated liver failure following bone marrow transplantation. J Hepatol 27 3 (1997) 572-577
104. Lau G.K., Lee C.K., and Liang R. Hepatitis B virus infection and bone marrow transplantation. Crit Rev Oncol Hematol 31 1 (1999) 71-76
105. Higashiyama H., Harabayashi H., Shinohara H., et al. Reactivation of hepatitis in a bladder cancer patient receiving chemotherapy. Int Urol Nephrol 39 2 (2007) 461-463
106. Yagci M., Acar K., Sucak G.T., et al. A prospective study on chemotherapy-induced hepatitis B virus reactivation in chronic HBs Ag carriers with hematologic malignancies and pre-emptive therapy with nucleoside analogues. Leuk Lymphoma 47 8 (2006) 1608-1612
107. Sera T., Hiasa Y., Michitaka K., et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med 45 11 (2006) 721-724
108. Perceau G., Diris N., Estines O., et al. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol 155 5 (2006) 1053-1056
109. Law J.K., Ali J.A., Harrigan P.R., et al. Fatal postlymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a YMDD mutant strain with lamivudine resistance in a noncirrhotic patient. Am J Hematol 81 12 (2006) 969-972
110. Cheng A.L., Hsiung C.A., Su I.J., et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 37 6 (2003) 1320-1328
111. Ohtsu T., Sai T., Oka M., et al. Activation of hepatitis B virus infection by chemotherapy containing glucocorticoid in hepatitis B virus carriers with hematologic malignancies. Jpn J Clin Oncol 21 5 (1991) 360-365
112. Liaw Y.F. Hepatitis viruses under immunosuppressive agents. J Gastroenterol Hepatol 13 1 (1998) 14-20
113. Skrabs C., Muller C., Agis H., et al. Treatment of HBV-carrying lymphoma patients with rituximab and CHOP: a diagnostic and therapeutic challenge. Leukemia 16 9 (2002) 1884-1886
114. Tsutsumi Y., Kanamori H., Mori A., et al. Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 4 3 (2005) 599-608
115. Coiffier B. State-of-the-art therapeutics: diffuse large B-cell lymphoma. J Clin Oncol 23 26 (2005) 6387-6393
116. Coiffier B. First-line treatment of follicular lymphoma in the era of monoclonal antibodies. Clin Adv Hematol Oncol 3 6 (2005) 484-491 505
117. Czuczman M.S., Grillo-Lopez A.J., White C.A., et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17 1 (1999) 268-276
118. Dervite I., Hober D., and Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 344 1 (2001) 68-69
119. Coiffier B. Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: role of lamivudine prophylaxis. Cancer Invest 24 5 (2006) 548-552
120. Rastetter W., Molina A., and White C.A. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med 55 (2004) 477-503
121. Hsu C.H., Hsu H.C., Chen H.L., et al. Doxorubicin activates hepatitis B virus (HBV) replication in HBV-harboring hepatoblastoma cells: a possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy. Anticancer Res 24 5A (2004) 3035-3040
122. Hamaki T., Kami M., Kusumi E., et al. Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab. Am J Hematol 68 4 (2001) 292-294
123. Grellier L., and Dusheiko G.M. Hepatitis B virus and liver transplantation: concepts in antiviral prophylaxis. J Viral Hepat 4 Suppl 1 (1997) 111-116
124. Floreani A., Boninsegna S., Lobello S., et al. Fatal hepatic decompensation in a bone marrow transplant recipient with HBV-related cirrhosis following lamivudine withdrawal. Gastroenterol Clin Biol 30 2 (2006) 307-309
125. Idilman R. Anti-viral prophylaxis in inactive hepatitis B virus carriers with hemato-oncological malignancies who receive chemotherapy. Minerva Gastroenterol Dietol 52 1 (2006) 39-45
126. Idilman R. Duration of lamivudine prophylaxis in inactive hepatitis B virus carriers with haemato/oncological malignancies who receive chemotherapy. Gut 55 8 (2006) 1208-1209
127. Nagamatsu H., Itano S., Nagaoka S., et al. Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy. Am J Gastroenterol 99 12 (2004) 2369-2375
128. Majluf-Cruz A., Luna-Castanos G., Trevino-Perez S., et al. Lamivudine-induced pure red cell aplasia. Am J Hematol 65 3 (2000) 189-191
129. Hester E.K., and Peacock Jr. J.E. Profound and unanticipated anemia with lamivudine-zidovudine combination therapy in zidovudine-experienced patients with HIV infection. AIDS 12 4 (1998) 439-440
130. Tseng A., Conly J., Fletcher D., et al. Precipitous declines in hemoglobin levels associated with combination zidovudine and lamivudine therapy. Clin Infect Dis 27 4 (1998) 908-909
131. Endo T., Sawada K., Fujimoto K., et al. [Reactivation of hepatitis B virus after autologous peripheral blood stem cell transplantation in patients with positive hepatitis B surface antibodies]. Rinsho Ketsueki 41 4 (2000) 322-328 [in Japanese]
132. Zoulim F. Detection of hepatitis B virus resistance to antivirals. J Clin Virol 21 3 (2001) 243-253
133. Lai C.L., Chien R.N., Leung N.W., et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 339 2 (1998) 61-68
134. Chang T.T., Lai C.L., Chien R.N., et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 19 11 (2004) 1276-1282
135. Hsiao L.-T., Chiou T.-J., Liu J.-H., et al. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 12 1 (2006) 84-94
136. Lok A.S., Lai C.L., Leung N., et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125 6 (2003) 1714-1722
137. Chen P.M., Yao N.S., Wu C.M., et al. Detection of reactivation and genetic mutations of the hepatitis B virus in patients with chronic hepatitis B infections receiving hematopoietic stem cell transplantation. Transplantation 74 2 (2002) 182-188
138. Pelizzari A.M., Motta M., Cariani E., et al. Frequency of hepatitis B virus mutant in asymptomatic hepatitis B virus carriers receiving prophylactic lamivudine during chemotherapy for hematologic malignancies. Hematol J 5 4 (2004) 325-328
139. Caccamo L., Romeo R., Rossi G., et al. No hepatitis recurrence using combination prophylaxis in HBV-positive liver transplant recipients with YMDD mutants. Transpl Int 18 2 (2005) 186-192
140. Pallier C., Castera L., Soulier A., et al. Dynamics of hepatitis B virus resistance to lamivudine. J Virol 80 2 (2006) 643-653
141. Fung S.K., Andreone P., Han S.H., et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 43 6 (2005) 937-943
142. Lampertico P.P., Viganò M.M., Manenti E.E., et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 42 6 (2005) 1414-1419
143. Benhamou Y.Y., Thibault V.V., Vig P.P., et al. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol 44 1 (2006) 62-67
144. Cortelezzi A., Vigano M., Zilioli V.R., et al. Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H. J Clin Virol 35 4 (2006) 467-469
145. Dore G.J., Guan R., Wasim Jafri S.M., et al. Management of chronic hepatitis B in challenging patient populations. Liver Int 26 Suppl 2 (2006) 38-46
146. Dan Y.Y., Wai C.T., Yeoh K.G., et al. Prophylactic strategies for hepatitis B patients undergoing liver transplant: a cost-effectiveness analysis. Liver Transpl 12 5 (2006) 736-746
147. Polak W.G., Andrzej, and Rotter K. Prevention of hepatitis B recurrence after liver transplantation. Ann Transplant 10 3 (2005) 11-16
148. Owens D.K. Interpretation of cost-effectiveness analyses. J Gen Intern Med 13 10 (1998) 716-717
149. Liaw Y.F., Leung N.W., Chang T.T., et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 119 1 (2000) 172-180
150. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131 6 (2006) 1743-1751
151. Colonno R.J., Rose R., Baldick C.J., et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 44 6 (2006) 1656-1665
152. Tenney D.J., Levine S.M., Rose R.E., et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 48 9 (2004) 3498-3507
153. Tenney D.J., Rose R.E., Baldick C.J., et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 51 3 (2007) 902-911